

Healthia Limited (the Company)

Continuous Disclosure Policy

1. Background

1.1 Overview

ASX Listing Rules require that the ASX be immediately notified should the Company become aware of information concerning it that is not generally available and which a reasonable person would expect to have a material effect on the price or value of the Company's securities.

The Company is committed to effective and timely communication with its customers, shareholders, market participants, employees, suppliers, financiers, creditors, other stakeholders and the wider community.

The Company will endeavour to make publicly available all information to ensure that trading in its shares takes place in an efficient, competitive and informed market.

2. Application

2.1 Scope

This Policy applies to all officers and employees of the Group.

No officer or employee of the Group may disclose material or price sensitive information regarding the Company except as provided for in this Policy.

This Policy operates in conjunction with other policies adopted by the Company.

2.2 Responsibility

The Company Secretary is primarily responsible for:

- (a) Ensuring the implementation and enforcement of this Policy; and
- (b) Ensuring all relevant information is disclosed to the ASX in accordance with the Company's obligations under the Act and ASX Listing Rules.

3. Market Communication

3.1 Preparing announcements

The Company shall ensure that any information disclosed to the ASX in accordance with this Policy shall:

- (a) Be disclosed in a timely manner in accordance with the ASX Listing Rules;
- (b) Be factual;
- (c) Not omit material information; and
- (d) Be expressed in a clear and objective manner.

3.2 *Releasing announcements*

The Board will approve all Company announcements, other than administrative announcements (or media releases that are not market sensitive), prior to release.

All market sensitive disclosures will first be made available on the ASX.

The Company Secretary will provide the Board of the Company with a copy of all market announcements promptly after release on the ASX.

3.3 *Analyst and investor briefings and presentations*

The Company will not disclose market sensitive information to any analyst or investor unless it has first provided that information to the market and received an acknowledgement that the information has been released.

The Company may hold meetings with analysts and/or investors as part of its investor relations program. The Company considers that such meetings facilitate effective two-way communication. In such meetings, The Company will not disclose market sensitive information unless it has first provided that information to the market.

Any new and substantive analyst or investor presentations will be released on the ASX prior to the presentation.

3.4 *Analyst reports and forecasts*

The Chief Financial Officer or their delegate will monitor analyst reports and forecasts to determine whether the forecasts diverge materially from the Company's internal earnings forecasts, monthly performance and (if applicable) any guidance published by the Company. If so, the Chief Financial Officer will consider whether The Company is required to make further disclosure.

3.5 *Only authorised personnel may communicate with third parties*

Only the Chairman, Managing Director, Chief Executive Officer and Chief Financial Officer are authorised to speak on behalf of the Company.

The Managing Director or Chief Executive Officer may from time to time authorise others to speak on behalf of the Company, whether generally or in respect to specific matters only.

All requests for external comment are to be referred to the applicable authorised spokesperson.

The Company spokesperson must not comment upon price sensitive information that has not previously been disclosed to the ASX in accordance with this Policy.

[End of document]